Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.40 |
| ▸ | CALCA | P06881 | 9/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015378 | 0.92 | CALCA (0.43) | LIPGCALCACYP2C9TP53THRB | |
| SCHEMBL3844219 | 0.89 | LIPG (0.41) | LIPGCALCACYP3A4CYP2C19SCN2A | |
| SCHEMBL3840244 | 0.87 | LIPG (0.39) | LIPGCALCACYP3A4CYP2C19SCN2A | |
| SCHEMBL3841153 | 0.83 | LIPG (0.41) | LIPGCALCACYP2C9TP53THRB | |
| SCHEMBL13917566 | 0.83 | CALCA (0.44) | LIPGCALCACYP2C9TP53CYP3A4 | |
| SCHEMBL3844221 | 0.81 | CALCA (0.44) | LIPGCALCACYP3A4CYP2C19SCN2A | |
| SCHEMBL3836454 | 0.81 | CALCA (0.44) | LIPGCALCACYP3A4CYP2C19SCN2A | |
| SCHEMBL5015341 | 0.80 | CALCA (0.40) | LIPGCALCACYP2C9KCNH2 | |
| SCHEMBL3840245 | 0.79 | CALCA (0.43) | LIPGCALCACYP3A4CYP2C19SCN2A | |
| SCHEMBL13917556 | 0.79 | CALCA (0.46) | LIPGCALCACYP2C9TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1749011-B1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-29 | — | — | EP | claimed |
| US-7176196-B2 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | claimed |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | CCNI, TYMP, IMPDH1 | LIPG 4606/4885CALCA 2267/4885CYP2C9 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.